Friday, July 22, 2016 12:16:16 PM
As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place of standard daily finger-stick blood testing.
Dexcom wants regulatory approval so that the information gathered by the device from a patient could be used to administer insulin without the standard fingerstick-based blood reading. If approved by the agency, analysts have said Dexcom could eventually garner Medicare coverage and grow the use of its device by as much as 23%.
The Clinical Chemistry and Clinical Toxicology Devices Panel, which met Thursday, voted 8-2 to support that there is reasonable assurance that the G5 Mobile CGM system is safe for the proposed indications for use.
It voted 9-1 that there is reasonable assurance that the device is effective for the proposed indications for use, and in an 8-2 vote, supported the benefits of the G5 Mobile CGM system outweighed the risks for the proposed indications for use.
"This recommendation is a big milestone for people with diabetes," Kevin Sayer, DexCom’s president and CEO, said in a statement, “We commend the FDA for bringing this important subject into a public forum, and thank the panel members, as well as the public speakers for their willingness to participate.”
Still, there was some concern before going into the panel review. Those concerns centered on the heavy reliance of data from computer simulation studies and the limitations of the human factor studies conducted by Dexcom, according to a review by Jefferies, a securities firm that rates Dexcom shares a buy.
Additional discussion at the review focused on how a majority of CGM patients already make dosing decisions based on information gathered by the devices and there might need to be appropriate training, which is only possible by a labeled indication. It was suggested by the panel that training instructions be detailed on the label itself.
Perhaps one of the key takeaways is that the regulatory agency and Dexcom remain in discussions about a post-marketing study design, which will have to be locked down before final FDA approval is granted. Wall Street analysts believe the final decision on that study could establish a clinical standard that all other devicemakers will need to meet if they want to secure a dosing claim for their own CGMs.
Recent DXCM News
- Exxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in Earnings • IH Market News • 04/26/2024 11:47:51 AM
- Dexcom Reports First Quarter 2024 Financial Results • Business Wire • 04/25/2024 08:03:00 PM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Dexcom Publishes Annual Sustainability Report • Business Wire • 04/03/2024 01:00:00 PM
- Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time • Business Wire • 04/02/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/07/2024 09:04:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 09:47:23 PM
- Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter • Business Wire • 03/05/2024 09:26:00 PM
- Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD • Business Wire • 03/05/2024 06:20:00 PM
- Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD • Business Wire • 03/05/2024 08:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 09:07:44 PM
- Dexcom Announces Upcoming Conference Presentation • Business Wire • 02/27/2024 09:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 10:31:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:48:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:09:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:02:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:15:27 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/08/2024 10:14:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:03:15 PM
- Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results • Business Wire • 02/08/2024 09:02:00 PM
- U.S. Index Futures Dip Slightly, Oil Prices Climb • IH Market News • 02/08/2024 10:56:39 AM
- Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People • Business Wire • 02/06/2024 07:00:00 AM
- Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time • Business Wire • 01/23/2024 01:30:00 PM
- Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland • Business Wire • 01/19/2024 07:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 11:56:20 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM